Join Now

Author Archives: admin

Kelvyn Cullimore Joins KSL Radio’s Inside Sources

SALT LAKE CITY, January 23, 2025—Today BioUtah president and CEO Kelvyn Cullimore joined KSL Radio’s Inside Sources to discuss the life sciences industry in the State of Utah. Hosted by Maura Carabello and Adam Gardiner, Inside Sources daily broadcast covers political issues affecting Utah. Today, Carabello and Gardiner interviewed Cullimore to spotlight Utah’s life sciences industry and […]

Posted in BioUtah News | Comments Off on Kelvyn Cullimore Joins KSL Radio’s Inside Sources

ARUP Offers New Assay To Detect Influenza A (H5) Virus

SALT LAKE CITY, January 3, 2025—ARUP Laboratories today launched a new assay for the detection and subtyping of influenza A (H5) virus. This test will aid in the evaluation of individuals who may have been exposed to highly pathogenic avian influenza (HPAI) A virus, also known as H5N1 or bird flu. In early 2024, an outbreak […]

Posted in BioUtah News | Comments Off on ARUP Offers New Assay To Detect Influenza A (H5) Virus

NUSANO NAMES MEDICAL RADIOISOTOPES ADVISORY BOARD

VALENCIA, Calif. – Dec. 3, 2024 – Nusano, a physics company transforming the production of radioisotopes, today announced the creation of a Medical Radioisotopes Advisory Board. This panel of internationally recognized leaders in nuclear medicine will provide strategic guidance to Nusano, ensuring its product development aligns with emerging trends and with the needs of cancer […]

Posted in BioUtah News | Comments Off on NUSANO NAMES MEDICAL RADIOISOTOPES ADVISORY BOARD

Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.’s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India. In support of the “Make […]

Posted in BioUtah News | Comments Off on Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)

LEHI, Utah, Dec. 10, 2024 /PRNewswire/ — Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today promising topline data resulting in the advancement to the second stage of its Phase 2 clinical trial evaluating HT-6184, a first-in-class allosteric NEK7/NLRP3 inflammasome inhibitor given orally, in patients with lower-risk […]

Posted in BioUtah News | Comments Off on Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)

PhotoPharmics to Present Patient Interest Findings from Groundbreaking Remote Parkinson’s Trial at PSG Annual Meeting

Presentation to Highlight Feasibility and Interest in Decentralized Home-Based Phase 3 Trial Salt Lake City, Utah — December 5, 2024 — PhotoPharmics, a pioneer in non-invasive phototherapy for neurological disorders, today announced it will present a poster titled “An Entirely Remote, Home-based Phase 3 Clinical Trial of a Specialized Light Therapy Device for Parkinson’s Disease […]

Posted in BioUtah News | Comments Off on PhotoPharmics to Present Patient Interest Findings from Groundbreaking Remote Parkinson’s Trial at PSG Annual Meeting

Fluidx Medical Begins Multinational Trial of GPX Embolic Device

November 27, 2024—Fluidx Medical Technology, Inc. announced that the first patient has been treated in the prospective, multinational, clinical trial of the company’s GPX embolic device. The device was successfully used in a portal vein embolization procedure in preparation for hepatic resection. According to the company, the safety and effectiveness trial includes leading medical centers […]

Posted in BioUtah News | Comments Off on Fluidx Medical Begins Multinational Trial of GPX Embolic Device

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor BIIB122 (DNL151) in participants with LRRK2-associated Parkinson’s disease (LRRK2-PD). LRRK2 inhibition is a potential therapeutic approach that […]

Posted in BioUtah News | Comments Off on Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

Cellino Appoints Chris Gibson to Board of Directors

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company’s Board of Directors. “Cellino’s proprietary technology stack, including optical bioprocessing, closed cassettes, and image-guided co-pilots, has the potential to transform healthcare and bring potentially curative therapies to millions of […]

Posted in BioUtah News | Comments Off on Cellino Appoints Chris Gibson to Board of Directors

Recursion and Google Cloud Announce Expansion of Partnership to Support Drug Discovery with Cloud and Exploration of Generative AI Technologies

SALT LAKE CITY and SUNNYVALE, Calif., Oct. 21, 2024 /PRNewswire/ — Recursion, a leading TechBio company decoding biology to radically improve lives, and Google Cloud today announced an expanded collaboration leveraging Google Cloud’s technologies to support Recursion’s drug discovery platform. This strategic partnership includes exploring generative AI capabilities, including Gemini models, to support the RecursionOS, […]

Posted in BioUtah News | Comments Off on Recursion and Google Cloud Announce Expansion of Partnership to Support Drug Discovery with Cloud and Exploration of Generative AI Technologies

U Announces Life-Saving Lab Pushing Limits of Medical Technology

The University of Utah, one of the nation’s leading research universities, has just announced the launch of a new laboratory called the Applied MedicalEngineering (AME) Lab. The AME Lab’s ambitious mission is to create cutting-edge medical technologies designed to deliver life-saving care to any patient with any injury at any location for any duration. The […]

Posted in BioUtah News | Comments Off on U Announces Life-Saving Lab Pushing Limits of Medical Technology

NUSANO AND STARGET PHARMA ANNOUNCE SUPPLY AGREEMENT TO ACCELERATE SMART TARGETED RADIOLIGAND DEVELOPMENT

VALENCIA, Calif. and TEL AVIV, Israel – Oct. 17, 2024 – Nusano, a physics company transforming the production of radioisotopes, and Starget Pharma, a clinical-stage biotechnology company developing precision peptide radioligand therapies focused on difficult to treat cancers, today announced a supply agreement to advance the development of Starget’s Smart Targeted Radioligands (STRs). The supply […]

Posted in BioUtah News | Comments Off on NUSANO AND STARGET PHARMA ANNOUNCE SUPPLY AGREEMENT TO ACCELERATE SMART TARGETED RADIOLIGAND DEVELOPMENT